[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
1. Kim JK, Hahn JS, Kim GE, Yang WI: Three cases of diffuse large B-cell lymphoma presenting as primary splenic lymphoma. Yonsei Med J; 2005 Oct 31;46(5):703-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of diffuse large B-cell lymphoma presenting as primary splenic lymphoma.
  • Primary splenic lymphoma (PSL) is often defined as generalized lymphoma with splenic involvement as the dominant feature.
  • We investigated three cases of non-Hodgkin's splenic lymphoma that had different clinical features on presentation.
  • The patients' survival times from diagnosis ranged from 59 to 143 months, without evidence of relapse after splenectomy and chemotherapy, with or without radiotherapy.
  • Further studies are needed to evaluate the impact that different treatment modalities without splenectomy have on patient survival.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Splenic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Haematol. 2000 Mar;64(3):145-50 [10997879.001]
  • [Cites] Am J Clin Pathol. 1965 Apr;43:332-3 [14275850.001]
  • [Cites] Cancer. 1966 Apr;19(4):461-9 [5327041.001]
  • [Cites] Arch Intern Med. 1971 Feb;127(2):259-65 [5101153.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1606-19 [6548171.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2460-7 [6388805.001]
  • [Cites] Cancer. 1988 Oct 1;62(7):1433-8 [3416282.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2612-9 [2249201.001]
  • [Cites] Am J Hematol. 1991 Oct;38(2):95-100 [1951314.001]
  • [Cites] Surgery. 1992 Feb;111(2):224-7 [1736393.001]
  • [Cites] J Nucl Med. 1992 Jun;33(6):1183-5 [1597736.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):207-15 [8416717.001]
  • [Cites] Haematologica. 1994 May-Jun;79(3):286-93 [7926983.001]
  • [Cites] Yonsei Med J. 1997 Oct;38(5):270-84 [9409190.001]
  • [Cites] Clin Radiol. 1998 Feb;53(2):137-42 [9502091.001]
  • [Cites] Surg Gynecol Obstet. 1965 May;120:947-60 [14269844.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3731-3 [11054447.001]
  • (PMID = 16259071.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2810579
  •  go-up   go-down


2. Hauswirth AW, Skrabs C, Schützinger C, Raderer M, Chott A, Valent P, Lechner K, Jäger U: Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. Haematologica; 2008 Mar;93(3):447-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune thrombocytopenia in non-Hodgkin's lymphomas.
  • Autoimmune thrombocytopenia is a common immunehematologic complication in non-Hodgkin's lymphomas and may complicate the treatment.
  • We analyzed an original series from our institute as well as published cases of non-Hodgkin's lymphomas (excluding chronic lymphocytic leukemia) associated with autoimmune thrombocytopenia with regard to demographic factors, prevalence in non-Hodgkin's lymphoma subtypes and treatment outcome.
  • Half of the cases occurred prior to diagnosis of lymphoma.
  • Chemotherapy is the best treatment in many non-Hodgkin's lymphomas patients with autoimmune thrombocytopenia compared with standard treatment of autoimmune thrombocytopenia.
  • Splenectomy is effective in splenic marginal zone lymphoma.
  • Autoimmune thrombocytopenia in patients with non-Hodgkin's lymphomas is potentially life-threatening and difficult to treat.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Purpura, Thrombocytopenic, Idiopathic / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Comorbidity. Female. Humans. Leukemia, Hairy Cell / drug therapy. Leukemia, Hairy Cell / epidemiology. Male. Middle Aged. Multiple Myeloma / epidemiology. Peripheral Blood Stem Cell Transplantation. Postoperative Complications / epidemiology. Prevalence. Splenectomy. Treatment Outcome. Waldenstrom Macroglobulinemia / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18287133.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Han SM, Teng CL, Hwang GY, Chou G, Tsai CA: Primary splenic lymphoma associated with hemophagocytic lymphohistiocytosis complicated with splenic rupture. J Chin Med Assoc; 2008 Apr;71(4):210-3
Genetic Alliance. consumer health - Hemophagocytic Lymphohistiocytosis (HLH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary splenic lymphoma associated with hemophagocytic lymphohistiocytosis complicated with splenic rupture.
  • Primary splenic lymphoma (PSL) is a rare disease with ambiguous definition, comprising less than 1% of non-Hodgkin's lymphoma.
  • Refusing diagnostic splenectomy, he received chemotherapy.
  • Spontaneous splenic rupture occurred after chemotherapy.
  • He received another 5 courses of chemotherapy with the R-CNOP regimen (rituximab, cyclophosphamide, mitoxantrone, vincristine, prednisolone).
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / complications. Lymphoma, Large B-Cell, Diffuse / complications. Splenic Neoplasms / complications. Splenic Rupture / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18436505.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


Advertisement
4. Perfetto F, Tarquini R, Mancuso F, Di Lollo S, Tozzini S, Bellesi G, Laffi G: Hepato-splenic lymphoma: a rare entity mimicking acute hepatitis: a case report. World J Gastroenterol; 2003 Jun;9(6):1381-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepato-splenic lymphoma: a rare entity mimicking acute hepatitis: a case report.
  • We reported a case of non-Hodgkin's lymphoma where liver involvement was the predominant clinical manifestation.
  • Bone marrow biopsy showed an intracapillary infiltration of T-lymphocytes with no evidence of lipid storage disease.
  • Because of a progressive spleen enlargement, splenectomy was performed.
  • Histological examination showed lymphomatous intrasinuses invasion of the spleen.
  • Immunohistochemical investigation revealed the T phenotype of the neoplastic cells: CD45+, CD45RO+, CD3+, CD4-, CD8-, TIA1-.
  • The diagnosis of hepatosplenic T cell lymphoma was done.
  • The patient was treated with chemotherapy, which induced a complete remission.
  • In spite of autologous bone marrow transplantation, he died twenty months after the diagnosis.
  • Even in the absence of a mass lesion or lymphoadenopathy, hepatosplenic T-cell lymphoma should be considered in the differential diagnosis of a patient whose clinical course is atypical for acute hepatic dysfunction.
  • [MeSH-major] Hepatitis / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Splenic Neoplasms / diagnosis
  • [MeSH-minor] Acute Disease. Adult. Diagnosis, Differential. Humans. Male


5. Ruiz-Hernández G, Scaglione C, Delgado-Bolton RC, Gutiérrez-García A, Madero L, Jiménez-Vicioso A, Carreras-Delgado JL: [Splenic and bone marrow increased 18F-FDG uptake in a PET scan performed following treatment with G-CSF]. Rev Esp Med Nucl; 2004 Mar-Apr;23(2):124-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Splenic and bone marrow increased 18F-FDG uptake in a PET scan performed following treatment with G-CSF].
  • Biopsy of the mediastinal mass revealed the presence of diffuse large B-cell non-Hodgkin's lymphoma.
  • Treatment included 4 cycles of chemotherapy followed by 7 days of subcutaneous granulocyte colony-stimulating factor (G-CSF, Lenogastrim) at a dose of 5 mg/Kg/day.
  • Following treatment, a CT scan was performed to evaluate response, finding a calcification of the mass without significant reduction of the overall size.
  • Because CT was inconclusive in the assessment of response to therapy, a 18F-FDG PET scan was performed.
  • The 18F-FDG PET scan did not show any pathological uptake in the mediastinum but revealed a splenic and bone marrow diffusely increased 18F-FDG uptake.
  • The differential diagnosis included a secondary effect induced by G-CSF therapy as one of the main possibilities, but other possibilities such as a malignant infiltration by lymphoma could not be discarded.
  • This study showed no pathological findings, with a normal 18F-FDG uptake in the spleen and bone marrow.
  • Thus, the benign and reactive nature of the splenic and bone marrow 18F-FDG increased uptake found in the previous study was confirmed.
  • We consider that the stimulating effect that G-CSF therapy has on the spleen and bone marrow must be taken into account when performing a 18F-FDG PET scan, as it can be an important source of false-positive results.
  • [MeSH-major] Bone Marrow / metabolism. Bone Marrow / radionuclide imaging. Fluorodeoxyglucose F18 / metabolism. Granulocyte Colony-Stimulating Factor / adverse effects. Radiopharmaceuticals / metabolism. Spleen / metabolism. Spleen / radionuclide imaging. Tomography, Emission-Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15000944.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


6. De Renzo A, Perna F, Persico M, Notaro R, Mainolfi C, de Sio I, Ciancia G, Picardi M, Del Vecchio L, Pane F, Rotoli B: Excellent prognosis and prevalence of HCV infection of primary hepatic and splenic non-Hodgkin's lymphoma. Eur J Haematol; 2008 Jul;81(1):51-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent prognosis and prevalence of HCV infection of primary hepatic and splenic non-Hodgkin's lymphoma.
  • BACKGROUND: Primary Hepatic (PHL) and Primary Splenic (PSL) non-Hodgkin's Lymphoma are rare entities.
  • Small series of PHL and PSL have been reported, suggesting a non-fortuitous association with Hepatitis C Virus (HCV) infection.
  • Twenty-four patients had a B-cell lymphoma, defined as Diffuse Large B-cell lymphoma in 18.
  • Combination chemotherapy was the mainstay of treatment for PHL and PSL; all but one patient with PSL underwent splenectomy before chemotherapy.
  • Complete remission was achieved in all the cases after frontline therapy; only four patients relapsed but responded to additional chemotherapy courses.
  • HCV infection did not appear to influence the results of therapy.
  • [MeSH-major] Hepatitis C / complications. Liver Neoplasms / virology. Lymphoma, Non-Hodgkin / virology. Splenic Neoplasms / virology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse. Male. Middle Aged. Prevalence. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18397390.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


7. Manipadam MT, Viswabandya A, Srivastava A: Primary splenic marginal zone lymphoma with florid granulomatous reaction--a case report and review of literature. Pathol Res Pract; 2007;203(4):239-43
Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary splenic marginal zone lymphoma with florid granulomatous reaction--a case report and review of literature.
  • Splenic marginal zone lymphomas (SMZL) constitute about 20% of primary splenic NHLs.
  • We report a case of primary SMZL with a florid granulomatous reaction which obscured the underlying lymphoma.
  • Although granulomas have been described in splenic non-Hodgkin lymphoma, it can be extensive and mask the underlying lymphoma.
  • [MeSH-major] Granuloma / pathology. Lymphoma, Non-Hodgkin / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Anemia, Hemolytic, Autoimmune / complications. Anemia, Hemolytic, Autoimmune / drug therapy. Enzyme Inhibitors / therapeutic use. Humans. Immunohistochemistry. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Mycophenolic Acid / therapeutic use. Splenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17398014.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Enzyme Inhibitors; 0 / Immunosuppressive Agents; HU9DX48N0T / Mycophenolic Acid
  •  go-up   go-down


8. Koch CA, Pacak K: Abnormal ACTH-stimulation test in a patient with AIDS: adrenal insufficiency or toxoplasmosis? Endocr Regul; 2001 Jun;35(2):91-3
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On further evaluation, he was found to have recurrent Non-Hodgkin lymphoma (spleen) and intracranial toxoplasmosis, perhaps imitating or aggravating symptoms suggestive of adrenal insufficiency (AI).
  • We diagnosed secondary AI due to megace treatment and tapered this medication under simultaneous hydrocortisone replacement therapy.
  • We conclude that patients with AIDS on megace therapy should receive special attention in regards to the potential development of AI, especially in stress situations such as infections or pain.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Adrenal Insufficiency / diagnosis. Adrenocorticotropic Hormone. Toxoplasmosis, Cerebral / diagnosis
  • [MeSH-minor] Adult. Anti-Infective Agents / therapeutic use. Diagnosis, Differential. Humans. Male. Megestrol Acetate / antagonists & inhibitors. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11563937.001).
  • [ISSN] 1210-0668
  • [Journal-full-title] Endocrine regulations
  • [ISO-abbreviation] Endocr Regul
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 9002-60-2 / Adrenocorticotropic Hormone; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


9. Musteata VG, Corcimaru IT, Iacovleva IA, Musteata LZ, Suharschii IS, Antoci LT: Treatment options for primary splenic low-grade non-Hodgkin's lymphomas. Clin Lab Haematol; 2004 Dec;26(6):397-401
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options for primary splenic low-grade non-Hodgkin's lymphomas.
  • The purpose of this comparative study was to evaluate the response of primary splenic low-grade non-Hodgkin's lymphomas (NHL) to chemotherapy, splenectomy, and chemotherapy combined with splenectomy in order to elaborate the optimum treatment modality.
  • A total of 104 patients (age range: 15-82 years) with primary low-grade B-cell NHL of the spleen were comprised by our study.
  • Regarding the treatment modality, splenectomy was performed in 14 patients, early splenectomy and single-agent chemotherapy in 15, early splenectomy and combined chemotherapy in 19, single-agent chemotherapy in 23, and combined chemotherapy in 33.
  • The median remission duration turned out to be longer (74.5 months) in the group of patients with complete remissions attained by means of splenectomy and combined chemotherapy.
  • Local relapses in the spleen developed in 19 (72.7%) patients treated with combined chemotherapy and in 9 (90.0%), who had undergone single-agent chemotherapy.
  • The 5-year overall survival was 54.4% after splenectomy, 39.4% after single-agent chemotherapy, and 37.1% after combined chemotherapy, being significantly higher (P <0.05) after splenectomy and single-agent chemotherapy (67.2%), and splenectomy followed by combined chemotherapy (64.7%).
  • Early splenectomy combined with chemotherapy is the optimum treatment option for primary low-grade NHL of the spleen because of the superiority in complete remission rate, remission duration, and in overall survival rate.
  • Splenectomy leads to somatic compensation of patients, makes impossible local relapsing in the spleen, prevents continuous dissemination from the primary tumor site, and mostly corrects cytopenias, creating better conditions for chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / therapy. Splenectomy. Splenic Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15595997.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Foti R, Fazio P, Lizzio G, Leonardi R: [Angioedema: first manifestation of non-Hodgkin's lymphoma]. Ann Ital Med Int; 2002 Jul-Sep;17(3):185-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioedema: first manifestation of non-Hodgkin's lymphoma].
  • [Transliterated title] Angioedema: prima manifestazione di linfoma non Hodgkin.
  • In a 48-year-old male patient a diagnosis of a non-Hodgkin lymphoma was made after two episodes of angioedema.
  • Abdominal ultrasonography and computed tomography showed two solid splenic masses infiltrating the greater curvature of the stomach and a 2 cm aortic lymph node.
  • A diagnosis of anaplastic large-cells lymphoma CD30+, anaplastic lymphoma kinase negative was made.
  • The disappearance of the neoplastic gastric infiltration and the decrease in size of the aortic lymph node and splenic mass were achieved after chemotherapy.
  • [MeSH-major] Angioedema / etiology. Autoimmune Diseases / etiology. Complement C1 Inactivator Proteins / deficiency. Complement C1 Inactivator Proteins / immunology. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Autoantibodies / immunology. Biomarkers, Tumor / blood. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Proteins / analysis. Prednisone / administration & dosage. Spleen / pathology. Stomach / pathology. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Ital Med Int. 2002 Jul-Sep;17(3):143-5 [12402660.001]
  • (PMID = 12402667.001).
  • [ISSN] 0393-9340
  • [Journal-full-title] Annali italiani di medicina interna : organo ufficiale della Società italiana di medicina interna
  • [ISO-abbreviation] Ann. Ital. Med. Int.
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Complement C1 Inactivator Proteins; 0 / Neoplasm Proteins; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; VACOP-B protocol
  •  go-up   go-down


11. Salmon JS, Thompson MA, Arildsen RC, Greer JP: Non-Hodgkin's lymphoma involving the liver: clinical and therapeutic considerations. Clin Lymphoma Myeloma; 2006 Jan;6(4):273-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma involving the liver: clinical and therapeutic considerations.
  • Primary hepatic non-Hodgkin's lymphoma (NHL) is a rare disease that presents unique diagnostic and therapeutic challenges.
  • Secondary liver involvement by lymphoma is common and can complicate treatment decisions.
  • A review of the published case reports and the few larger series suggests that primary hepatic NHL represents a heterogeneous mixture of disparate diseases rather than a single entity.
  • The clinical, laboratory, and radiographic characteristics are nonspecific, which means the diagnosis is often not suspected until histopathologic examination of liver tissue.
  • There appears to be a strong association between primary hepatic NHL and the hepatitis C virus.
  • Hepatosplenic T-cell lymphoma has attained its own status as a unique disease, whereas case reports suggest that the spectrum of hepatic lymphoma includes many histologies.
  • Involvement of the liver by lymphoma can compound the difficulty of pursuing aggressive chemotherapy in patients who have a life-threatening illness and impaired metabolism of the most effective drugs.
  • Therapy should be tailored to the individual clinical situation, with consideration of the underlying histology and degree of hepatic insufficiency.
  • [MeSH-major] Liver Neoplasms / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Hepatitis C / complications. Hepatitis C / pathology. Hepatitis C / therapy. Humans. Liver Failure / etiology. Liver Failure / pathology. Liver Failure / therapy. Splenic Neoplasms / pathology. Splenic Neoplasms / secondary. Splenic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507204.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 92
  •  go-up   go-down


12. Coleman M, Kaufmann T, Nisce LZ, Leonard JP: Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation. Int J Radiat Oncol Biol Phys; 2000 Mar 15;46(5):1235-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation.
  • PURPOSE: At the New York Presbyterian Hospital-Cornell Medical Center, patients with unequivocal clinical stage I and IIA Hodgkin's disease (HD) have been treated with mantle, splenic, and extended field radiation therapy (EFRT) (without surgical staging).
  • Patients with pathological or equivocal staging, "B" symptoms, bulk disease, history of previous chemotherapy, and/or Stage III or IV disease were excluded from our analysis.
  • The median time to relapse was 38 months; mean time 42. 3 months.
  • All patients are alive, well and free of disease, including nine who received subsequent chemotherapy and one who underwent autotransplantation.
  • CONCLUSIONS: Careful clinical staging of early, asymptomatic HD patients treated with mantle, splenic, and EFRT may obviate the need for exploratory laparotomy.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Spleen

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10725636.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 07968
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


13. Win N, Tiwari D, Keevil VL, Needs M, Lakhani A: Mixed-type autoimmune haemolytic anaemia: unusual cases and a case associated with splenic T-cell angioimmunoblastic non-Hodgkin's lymphoma. Hematology; 2007 Apr;12(2):159-62
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed-type autoimmune haemolytic anaemia: unusual cases and a case associated with splenic T-cell angioimmunoblastic non-Hodgkin's lymphoma.
  • The diagnosis of mixed-type autoimmune haemolytic anaemia (AIHA) is based on demonstrating the presence of "warm" IgG auto-antibody and "low titre" ( < 64 at 4 degrees C), "high thermal amplitude" (reacting at or >30 degrees C) "cold" IgM auto-antibody.
  • Mixed-type AIHA is uncommon.
  • Red cell agglutination on the peripheral blood film is a common finding in mixed-type AIHA and can lead, initially, to a mis-diagnosis of cold haemmagglutinin disease (CHAD).
  • Mixed-type AIHA is rare and can be idiopathic or secondary, often associated with systemic lupus erythematosus (SLE) and lymphoma.
  • In general, patients with mixed-type AIHA show a dramatic response to steroid therapy and frequently require few or no transfusions.
  • We report two unusual cases of mixed-type AIHA.
  • Case one was unusual as the patient developed AIHA while on steroid medication.
  • Case two, we believe, is the first reported case of splenic T cell angioimmunoblastic non-Hodgkins lymphoma (NHL) associated with mixed-type AIHA.
  • The patient failed to respond to steroids, intravenous immunoglobulin, chemotherapy and treatment with rituximab.
  • DAT tested with monospecific reagents, and thorough serological investigations is required to reach the diagnosis of mixed-type AIHA.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / etiology. Anti-Inflammatory Agents / adverse effects. Lymphoma, T-Cell / complications. Paraneoplastic Syndromes / etiology. Prednisolone / adverse effects. Splenic Neoplasms / complications
  • [MeSH-minor] Aged. Antibodies, Anti-Idiotypic / blood. Antibodies, Anti-Idiotypic / immunology. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Autoantibodies / blood. Autoantibodies / immunology. Combined Modality Therapy. Complement C3d / immunology. Coombs Test. Cryoglobulins / analysis. Cryoglobulins / immunology. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Erythrocyte Transfusion. Fatal Outcome. Female. Humans. Immunoglobulin G / blood. Immunoglobulin G / immunology. Immunoglobulin M / blood. Immunoglobulin M / immunology. Immunoglobulins, Intravenous / therapeutic use. Immunosuppressive Agents / therapeutic use. Immunotherapy. Male. Osteoarthritis / drug therapy. Prednisone / administration & dosage. Rituximab. Splenectomy. Temperature. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454198.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Autoantibodies; 0 / Cryoglobulins; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Immunoglobulins, Intravenous; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80295-45-0 / Complement C3d; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


14. Asfour IA, El-Tehewi MM, Ahmed MH, Abdel-Sattar MA, Moustafa NN, Hegab HM, Fathey OM: High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin's lymphoma. Biol Trace Elem Res; 2009 Mar;127(3):200-10
Hazardous Substances Data Bank. SODIUM SELENITE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin's lymphoma.
  • The present study was undertaken to explore the effect of administration of high doses of sodium selenite on the apoptosis of lymphoma cells in patients with non-Hodgkin's lymphoma (NHL).
  • Group I received standard chemotherapy, whereas group II received adjuvant sodium selenite 0.2 mg kg(-1) day(-1) for 7 days in addition to chemotherapy.
  • Flow cytometry was used for monitoring of lymphoma cells apoptosis at the time of diagnosis and after therapy in the two groups.
  • Sodium selenite administration resulted in significant increase in percentage of apoptotic lymphoma cells after therapy in group II (78.9 +/- 13.3% versus 58.9 +/- 18.9%, p < 0.05).
  • In addition, patients who received sodium selenite treatment demonstrated statistically significant increase in percentage of reduction of cervical and axillary lymphadenopathy, decrease in splenic size, and decreased percentage of bone marrow infiltration.
  • It is concluded that sodium selenite administration at the dosage and duration chosen has synergistic effect to chemotherapy in inducing apoptosis and, consequently, could improve clinical outcome.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Apoptosis. Lymphoma, Non-Hodgkin / drug therapy. Sodium Selenite / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953506.001).
  • [ISSN] 1559-0720
  • [Journal-full-title] Biological trace element research
  • [ISO-abbreviation] Biol Trace Elem Res
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; HIW548RQ3W / Sodium Selenite
  •  go-up   go-down


15. De Sanctis V, Martelli M, Anticoli AP, Caronna R, Chirletti P, Giovannini M, Santarelli M, Enrici RM, Mandelli F: Localized stage I-IE aggressive non-Hodgkin's lymphoma (NHL): results of prospective study with multimodality therapeutic approach. Anticancer Res; 2001 Nov-Dec;21(6A):4169-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized stage I-IE aggressive non-Hodgkin's lymphoma (NHL): results of prospective study with multimodality therapeutic approach.
  • BACKGROUND: A brief course of chemotherapy followed by radiation therapy was considered the best treatment for localized high-grade Non-Hodgkin's Lymphoma (NHL).
  • The purpose of this study was to determine the efficacy and feasibility of a brief-course of anthracycline-based chemotherapy (CHOP) and consolidation radiation therapy (CRT) in a series of 57 consecutive patients with stage I-IE intermediate-high grade NHL.
  • Forty-four (77%) received a CRT and thirteen (23%) with primitive gastric and splenic NHL underwent radical surgery.
  • The 5-year OS, DFS and EFS was 100% in thirteen patients with primitive gastric or splenic NHL treated with a radical surgical approach followed by chemotherapy without CRT.
  • CONCLUSION: We confirm the efficacy and feasibility of a brief course of CHOP chemotherapy followed by CRT in localized I-IE intermediate-high grade NHL without adverse prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prospective Studies. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911313.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


16. Kahn ST, Flowers CR, Lechowicz MJ, Hollenbach K, Johnstone PA: Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients. Cancer J; 2005 Sep-Oct;11(5):425-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
  • This study assessed efficacy, optimal dosage and timing, and toxicity of involved-field radiotherapy used in conjunction with high-dose chemotherapy and stem cell transplantation for patients with refractory/relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
  • METHODS AND MATERIALS: 306 patients with refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma were analyzed.
  • Forty-one patients underwent involved-field radiotherapy in conjunction with high-dose chemotherapy and bone marrow or peripheral stem cell transplantation.
  • The other 265 patients with refractory/relapsed non-Hodgkin's lymphoma and Hodgkin's disease received high-dose chemotherapy/stem cell transplantation, but not involved-field radiotherapy.
  • RESULTS: There were 124 deaths during the follow-up period, including 17% of the patients treated with involved-field radiotherapy and 44.2% of the patients receiving chemotherapy without involved-field radiotherapy.
  • Multivariate analysis found that patients who did not receive involved-field radiotherapy were 2.09 times more likely to die during the follow-up period than patients who received involved-field radiotherapy (P = 0.066; adjusted for age, stem cell transplantation type, stage I/II vs stage III/IV, refractory vs relapsed, and Hodgkin's disease vs non-Hodgkin's lymphoma).
  • Five of the 41 patients treated with involved-field radiotherapy developed toxicity subsequent to treatment.
  • All but one of these patients had been treated with doses greater than 30 Gy.
  • [MeSH-major] Bone Marrow Transplantation. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / adverse effects. Female. Follow-Up Studies. Humans. Male. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / therapy. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pelvic Neoplasms / pathology. Pelvic Neoplasms / therapy. Proportional Hazards Models. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Retrospective Studies. Splenic Neoplasms / pathology. Splenic Neoplasms / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259874.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Zhang R, Wang D, Li Q, Sun T, Hao X: [Primary lymphoma of the spleen: clinical analysis of 23 cases]. Zhonghua Wai Ke Za Zhi; 2002 Mar;40(3):208-9
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary lymphoma of the spleen: clinical analysis of 23 cases].
  • OBJECTIVE: To investigate the best diagnostic and therapeutic method for primary lymphoma of the spleen.
  • They accepted chemotherapy after operation.
  • B-cell type non-Hodgkin's lymphoma was noted in 21 patients and T-cell letion in 2.
  • CONCLUSIONS: The diagnosis of splenic lymphoma is dependent mainly on B-ultrasound examination and CT scanning.
  • Splenectomy combined with chemotherapy may provide optimum therapy for patients with splenic lymphoma.
  • [MeSH-major] Lymphoma / surgery. Splenic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Drug Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Splenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11955418.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Grosskreutz C, Troy K, Cuttner J: Primary splenic lymphoma: report of 10 cases using the REAL classification. Cancer Invest; 2002;20(5-6):749-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary splenic lymphoma: report of 10 cases using the REAL classification.
  • Primary splenic lymphoma (PSL) is rare with a reported incidence of less than 1%.
  • Our objective was to evaluate staging (using the Ahmann and Kehoe criteria), prognosis using the International Prognostic Index (IPI), and pathology using the Revised European-American Lymphoma Classification (REAL) classification.
  • Eight of the 10 patients had diffuse large cell lymphoma (DLCL).
  • Lymph node involvement beyond the splenic hilum seen by imaging studies represents an advanced non-Hodgkin's lymphoma and should be included no longer in the staging of PSL.
  • Eight of the nine patients received chemotherapy following splenectomy.
  • Splenectomy followed by combination chemotherapy, results in excellent long-term survival in PSL.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Splenectomy. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12197231.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Singh A, Thapar V, Prabhu R, Naresh K, Joshi A, Supe A: Isolated splenic lymphoma: an elusive preoperative diagnosis. Indian J Gastroenterol; 2000 Oct-Dec;19(4):184-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated splenic lymphoma: an elusive preoperative diagnosis.
  • Four patients underwent splenectomy for various clinical and radiological diagnoses and were found to have primary splenic lymphoma at surgery and histology.
  • The diagnosis was classical Hodgkin's lymphoma, mixed cellularity type (one case); marginal zone B-cell non-Hodgkin's lymphoma (one case); and large B cell type non-Hodgkin's lymphoma (two cases).
  • The first two patients had multiple nodules in the spleen measuring 0.1-0.5 cm while large cell lymphomas had large nodules (largest measuring 11 cm x 7 cm x 4 cm).
  • Mean follow up of these patients was 11 months; all patients received chemotherapy.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / surgery. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / surgery. Splenic Diseases / diagnosis. Splenic Diseases / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intraoperative Period. Male. Middle Aged. Preoperative Care. Splenectomy / methods. Splenectomy / mortality. Splenomegaly / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11059187.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] INDIA
  •  go-up   go-down


20. Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW: Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol; 2009 Nov 10;27(32):5390-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
  • PURPOSE: This multicenter, prospective, randomized controlled trial compared the efficacy and toxicity of two chemotherapy regimens in advanced Hodgkin's lymphoma (HL): the weekly alternating Stanford V and the standard, twice-weekly regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).
  • Radiotherapy was administered in both arms to sites of previous bulk (> 5 cm) and to splenic deposits, although this was omitted in the latter part of the trial for patients achieving complete remission (CR) in the ABVD arm.
  • A total of 520 patients were randomly assigned and were assessed for the primary outcome measure of progression-free survival (PFS).
  • Five hundred patients received protocol treatment, and radiotherapy was administered to 73% in the Stanford V arm and to 53% in the ABVD arm.
  • RESULTS: The overall response rates after completion of all treatment were 91% for Stanford V and 92% for ABVD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Lung Diseases / chemically induced. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19738111.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN64141244
  • [Grant] United Kingdom / Cancer Research UK / / C2422/A2858
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


21. Illés A, Simon Z, Tóth E, Rosta A, Miltényi Z, Molnár Z: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres. Pathol Oncol Res; 2008 Dec;14(4):411-21
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
  • Clinicopathological features of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) differ from those of the classical Hodgkin lymphoma (cHL).
  • Our aim was to examine clinical presentation, therapeutic and survival results of NLPHL patients in Hungary based on the data of two centres, and incidentally we analyzed the clinicopathological characteristics and differential diagnostic difficulties of this rare entity.
  • We analyzed the clinical features, treatment and survival data of 536 Hodgkin lymphoma patients who had been diagnosed and primarily treated in our institutes between 1995 and 2004.
  • Mean follow-up time was 82.7 (3-144) months of the total 536 HL patients.
  • None of the patients showed extranodal or splenic involvement or bulky disease.
  • One patient received chemotherapy alone, six received only involved field radiotherapy while six underwent combined modality treatment.
  • Two NLPHL cases transformed to non-Hodgkin's lymphoma.
  • CONCLUSIONS: NLPHL is a rare disease, thus these are limited experiences with its diagnosis and treatment.
  • Since the disease has an excellent outcome, it is very important to prefer less toxic or local therapies to reach long term survival similar to that of the normal population.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / mortality. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Hungary. Immunohistochemistry. Lymphoma / pathology. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Sep 15;86(6):2312-20 [7662978.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1731-8 [11920535.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1221-9 [16094666.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):599-606 [3041849.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:77-82 [2049323.001]
  • [Cites] Hematol Oncol. 2006 Sep;24(3):146-50 [16729353.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Blood. 2008 Jan 1;111(1):109-11 [17938252.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3753-8 [12881319.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):903-11 [12826882.001]
  • [Cites] Semin Radiat Oncol. 2007 Jul;17(3):184-9 [17591565.001]
  • [Cites] Acta Haematol. 1986;76(1):29-32 [3098024.001]
  • [Cites] Orv Hetil. 2002 Mar 31;143(13):651-61 [11975042.001]
  • [Cites] Blood. 1989 Jan;73(1):47-56 [2462943.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1346-56 [14508396.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1683-7 [16093276.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2002 Sep 24;65(3):195-202 [12242134.001]
  • [Cites] Blood. 1996 Jul 15;88(2):657-66 [8695813.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1551-7 [15370206.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):128-32 [16330953.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1063-83 [5947336.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Oct;21(5):787-804 [17908620.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:266-72 [17124071.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S45-56 [9926237.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Oct;21(5):897-914 [17908627.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • (PMID = 18431694.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


22. Chanan-Khan A, Islam T, Alam A, Miller KC, Gibbs J, Barcos M, Czuczman MS, Paplham P, Hahn T, McCarthy P: Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma. Leuk Lymphoma; 2004 Aug;45(8):1673-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma.
  • Hepatosplenic T-cell non-Hodgkin's lymphoma (HSTCL) is a rare, aggressive form of NHL, with a median survival of approximately 8 months.
  • We were able to successfully induce complete remission in a patient with alpha/beta HSTCL who was refractory to multiple prior chemotherapy regimens, using the humanized anti-CD52 monoclonal antibody alemtuzumab (Campath).
  • These data suggest a potential role for alemtuzumab and allogeneic SCT in the treatment of T-cell NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Liver Neoplasms / therapy. Lymphocyte Transfusion. Lymphoma, T-Cell / therapy. Salvage Therapy. Splenic Neoplasms / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Humans. Male. Receptors, Antigen, T-Cell, alpha-beta / metabolism. Remission Induction. Survival Rate. Time Factors. Tissue Donors. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15370223.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Receptors, Antigen, T-Cell, alpha-beta; 3A189DH42V / alemtuzumab
  •  go-up   go-down


23. Daskalogiannaki M, Prassopoulos P, Katrinakis G, Tritou I, Eliopoulos G, Gourtsoyiannis N: Splenic involvement in lymphomas. Evaluation on serial CT examinations. Acta Radiol; 2001 May;42(3):326-32
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic involvement in lymphomas. Evaluation on serial CT examinations.
  • PURPOSE: To prospectively evaluate changes in splenic volume (SV) on serial CT of patients with lymphoma and correlate them with other indicators of the disease process.
  • MATERIAL AND METHODS: SV was calculated in 290 abdominal CT examinations of 58 consecutive adults with lymphoma (42 non-Hodgkin's lymphoma, 16 Hodgkin's disease).
  • Each patient had one CT investigation before, 2 during chemotherapy and 2 post-chemotherapy.
  • Group A (n=20) presented no changes in SV, showed no splenic parenchymal abnormalities and had normal SV and serum lactic dehydrogenase (S-LDH).
  • Group B (n=25) presented a decrease in SV during treatment suggesting response to therapy.
  • Splenic parenchymal abnormalities (n=5) and other subdiaphragmatic sites of involvement (n=20) underwent remission during treatment.
  • Eighteen patients with high S-LDH at presentation showed normal values during therapy.
  • Group C (n=12) showed an increase in SV post-therapy associated with manifestations of disease recurrence.
  • The S-LDH levels were elevated in 10 patients at the same time.
  • CONCLUSION: Quantitatively assessed splenic size on CT may serve as an indicator of splenic involvement in the course of lymphomas.
  • [MeSH-major] Lymphoma / radiography. Spleen / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11350294.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


24. Chisesi T, Polistena P, Contu A, Coser P, Indrizzi L, Leoni P, Majolino I, Porcellini A, Salvagno L, Zambaldi G, Rizzoli V, Congiu AM, Santini G, Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG): Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients. Leuk Lymphoma; 2001 Mar;41(1-2):125-36
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients.
  • Here we report the results of a randomised multicenter phase III clinical trial which assesses the therapeutic efficacy and tolerability of a chemotherapy protocol CEMP (cyclophosphamide, etoposide, mitoxantrone and prednisone) in adult and elderly patients with advanced intermediate and high-grade NHL.
  • Between October 1991 and October 1995, 139 patients, aged 55 to 79 years, with diffuse intermediate and high-grade lymphoma, were enrolled.
  • A considerable percentage of patients had clinically aggressive disease: 32.4% had systemic symptoms, 79% had stage III or IV disease, 33.8% had bone marrow involvement, 46% had splenic involvement and 42.5% had increased values of serum lactate dehydrogenate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Actuarial Analysis. Age Factors. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / standards. Cyclophosphamide / toxicity. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / standards. Etoposide / toxicity. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / standards. Mitoxantrone / toxicity. Prednisone / administration & dosage. Prednisone / standards. Prednisone / toxicity. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11342364.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CEMP protocol
  •  go-up   go-down


25. Reiser M, Diehl V: Current treatment of follicular non-Hodgkin's lymphoma. Eur J Cancer; 2002 Jun;38(9):1167-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment of follicular non-Hodgkin's lymphoma.
  • Most patients with follicular lymphoma are over 50 years of age and present with widespread disease at diagnosis.
  • Nodal involvement is very common, often accompanied by splenic and bone marrow disease.
  • The vast majority of patients with advanced stage follicular lymphoma are not cured using the current therapeutic options.
  • The rate of relapse is fairly consistent over time, even in patients who have achieved complete responses (CRs) to treatment.
  • Therapeutic options in follicular NHL include watchful waiting, oral alkylating agents, purine nucleoside analogues, combination chemotherapy, interferon and monoclonal antibodies.
  • The approval of rituximab, an unconjugated chimeric antibody against the CD20 antigen for the treatment of relapsed follicular B-cell NHL marked a milestone in the development of antibody treatment.
  • Various clinical trials combining monoclonal antibodies with conventional therapies are currently ongoing to determine whether these new biological agents will alter the natural history of follicular lymphoma.
  • [MeSH-major] Lymphoma, Follicular / therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation / methods. Hematopoietic Stem Cell Transplantation / methods. Humans. Interferons / therapeutic use. Middle Aged. Transplantation, Homologous

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12044501.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 9008-11-1 / Interferons
  • [Number-of-references] 44
  •  go-up   go-down


26. El Weshi A, Akhtar S, Mourad WA, Ajarim D, Abdelsalm M, Khafaga Y, Bazarbashi S, Maghfoor I: T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature. Leuk Lymphoma; 2007 Sep;48(9):1764-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature.
  • T-cell/histiocyte-rich B-cell lymphoma (TC/HRBCL) is a rare subtype of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with characteristic morphologic and immunophenotypic features, often misdiagnosed as Hodgkin's lymphoma and peripheral T-cell lymphoma.
  • Few and conflicting clinical data are available in the literature addressing optimal treatment, prognosis and outcome.
  • We retrospectively reviewed all patients diagnosed and managed at our institution between 1995 and 2004 diagnosed with T-cell-rich-B-cell lymphoma by WHO criteria.
  • Fifty-two percent of patients (32) had splenic involvement and thirty-seven patients (61%) presented with extranodal disease (22 >or= 2 sites).
  • All 59 newly diagnosed TC/HRBCL patients were treated with CHOP or R-CHOP combination chemotherapy +/- radiation therapy.
  • The overall response rate was 85% and nine patients progressed on therapy.
  • Fourteen patients relapsed with a median time of relapse of 6 months (range, 2 - 28).
  • Treatment outcome seems to be similar to IPI matched DLBCL counterpart.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Salvage Therapy. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Sep;48(9):1670-1 [17786700.001]
  • (PMID = 17786712.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 31
  •  go-up   go-down


27. Drini M, Prichard PJ, Brown GJ, Macrae FA: Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease. Med J Aust; 2008 Oct 20;189(8):464-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease.
  • Tumour necrosis factor inhibitors have revolutionised the management of Crohn's disease, but reports of a possible association between concomitant infliximab and immunomodulator therapy and hepatosplenic T-cell lymphoma (a rare form of aggressive non-Hodgkin's lymphoma) have emerged.
  • We describe the first case in Australia of hepatosplenic T-cell lymphoma in a patient who had been treated with infliximab and immunomodulators for Crohn's disease.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Liver Neoplasms / chemically induced. Lymphoma, T-Cell / chemically induced. Splenic Neoplasms / chemically induced. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Adult. Crohn Disease / drug therapy. Fatal Outcome. Humans. Immunologic Factors / adverse effects. Immunologic Factors / therapeutic use. Infliximab. Male

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. Infliximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Med J Aust. 2009 Mar 16;190(6):341-2 [19296822.001]
  • (PMID = 18928444.001).
  • [ISSN] 0025-729X
  • [Journal-full-title] The Medical journal of Australia
  • [ISO-abbreviation] Med. J. Aust.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunologic Factors; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  •  go-up   go-down


28. Chajari M, Lacroix J, Peny AM, Chesnay E, Batalla A, Henry-Amar M, Delcambre C, Génot JY, Fruchard C, Bardet S: Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography? Eur J Nucl Med Mol Imaging; 2002 Mar;29(3):380-7
Hazardous Substances Data Bank. GALLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography?
  • The usefulness and complementarity of gallium (67Ga) scintigraphy and computed tomography (CT) in the management of patients with lymphoma have been extensively demonstrated.
  • As fusion imaging techniques between single-photon emission tomography (SPET) and CT have been developed recently, we investigated whether use of CT/67Ga SPET fusion imaging could help in the interpretation of 67Ga scintigraphy.
  • From November 1999 to May 2001, 52 consecutive fusion studies were performed in 38 patients [22 patients with Hodgkin's disease (HD) and 16 patients with non-Hodgkin's lymphoma (NHL)] as part of pre-treatment staging (n=13), treatment evaluation (n=20) or evaluation of suspected recurrence (n=19).
  • Image fusion was considered to be of benefit in 12/52 (23%) studies which were performed for initial staging (n=4), treatment evaluation (n=4) or evaluation of suspected recurrence (n=4).
  • In these cases, image fusion allowed either confirmation and/or localisation of pathological gallium uptake (n=10) or detection of lesions not visible on CT scan (n=2).
  • In the abdomen and pelvis, fusion helped to differentiate physiological bowel elimination from abnormal uptake, and assisted in precisely locating uptake in neighbouring viscera of the left hypochondrium, including the spleen, left liver lobe, coeliac area, stomach wall and even the splenic flexure.
  • Clinical management was altered by fusion imaging in one patient (chemotherapy was given instead of radiotherapy) and was potentially affected in three other patients (in that, in conjunction with other factors, the results of fusion imaging had an influence on the decision regarding use of irradiation and especially the treatment volume).
  • In conclusion, CT/67Ga SPET fusion imaging allowed precise localisation of gallium uptake and correct attribution to the involved viscera, thereby altering the diagnosis in 20%-25% of studies in comparison with CT and 67Ga SPET analyses alone.
  • CT/67Ga SPET fusion therefore appears valuable in facilitating the interpretation of 67Ga scintigraphy and we recommend its use in patients with lymphoma when CT and 67Ga scintigraphy are planned.
  • [MeSH-major] Citrates. Gallium. Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12002715.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Citrates; 0 / Radiopharmaceuticals; 27905-02-8 / gallium citrate; CH46OC8YV4 / Gallium
  •  go-up   go-down


29. Hermine O, Lefrère F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, Delmas B, Valensi F, Cacoub P, Brechot C, Varet B, Troussard X: Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med; 2002 Jul 11;347(2):89-94
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection.
  • BACKGROUND: Some epidemiologic studies suggest a link between hepatitis C virus (HCV) infection and some B-cell non-Hodgkin's lymphomas.
  • We undertook this study after a patient with splenic lymphoma with villous lymphocytes had a hematologic response after antiviral treatment of HCV infection.
  • METHODS: Nine patients who had splenic lymphoma with villous lymphocytes and HCV infection were treated with interferon alfa-2b (3 million IU three times per week) alone or in combination with ribavirin (1000 to 1200 mg per day).
  • The outcomes were compared with those of six similarly treated patients with splenic lymphoma with villous lymphocytes who tested negative for HCV infection.
  • In contrast, none of the six HCV-negative patients had a response to interferon therapy.
  • CONCLUSIONS: In patients with splenic lymphoma with villous lymphocytes who are infected with HCV, treatment with interferon can lead to regression of the lymphoma.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepacivirus / pathogenicity. Hepatitis C / drug therapy. Interferon-alpha / therapeutic use. Lymphoma, B-Cell / virology. Splenic Neoplasms / virology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] N Engl J Med. 2002 Jul 11;347(2):78-9 [12110734.001]
  • [CommentIn] N Engl J Med. 2002 Dec 26;347(26):2168-70; author reply 2168-70 [12501232.001]
  • [CommentIn] N Engl J Med. 2002 Dec 26;347(26):2168-70; author reply 2168-70 [12501854.001]
  • [CommentIn] N Engl J Med. 2003 Nov 20;349(21):2078-9 [14627800.001]
  • [CommentIn] Gastroenterology. 2003 Apr;124(4):1157-8 [15534980.001]
  • [CommentIn] N Engl J Med. 2002 Dec 26;347(26):2168-70; author reply 2168-70 [12501855.001]
  • (PMID = 12110736.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / RNA, Viral
  •  go-up   go-down


30. Cohen AM, Grinblat B, Bessler H, Kristt D, Kremer A, Schwartz A, Halperin M, Shalom S, Merkel D, Don J: Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma; 2004 May;45(5):951-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma.
  • The aim of this study was to investigate whether the human Pim-2 (hPim-2) expression is altered in chronic lymphocytic leukemia (B-CLL) and non-Hodgkin's lymphomas (NHL).
  • In-situ hybridization revealed a 5.5 +/- 2.2 times higher expression of hPim-2 in NHL over normal lymphocytes (P < 0.001).
  • Similarly, with quantitative RT-PCR, expression in NHL was 1.5 to 2.6 times higher in involved splenic foci compared to nearby uninvolved regions (n = 3).
  • The increased hPim-2 levels correlated with lymphocyte doubling time (DT), in that mRNA levels were two times greater in patients with rapid DT (P < 0.006).
  • This relationship between hPim-2 and NHL and CLL raises a number of novel mechanistic options for the genesis and/or progression of some types of human lymphomas.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Protein-Serine-Threonine Kinases / genetics. Proto-Oncogene Proteins / genetics

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15291354.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / PIM2 protein, human; 0 / Proto-Oncogene Proteins; 0 / RNA, Neoplasm; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


31. Matsunaga T, Takemoto N, Miyajima N, Okuda T, Nagashima H, Sato T, Terui T, Sasaki H, Ohmi N, Hirayama Y, Tamura Y, Niitsu Y: Splenic marginal zone lymphoma presenting as myelofibrosis associated with bone marrow involvement of lymphoma cells which secrete a large amount of TGF-beta. Ann Hematol; 2004 May;83(5):322-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic marginal zone lymphoma presenting as myelofibrosis associated with bone marrow involvement of lymphoma cells which secrete a large amount of TGF-beta.
  • We report here on a patient with splenic marginal zone lymphoma presenting diffuse fibrosis of bone marrow and spleen.
  • After splenectomy and chemotherapy, bone marrow biopsy demonstrated an improvement of fibrosis.
  • Plasma concentration of transforming growth factor (TGF)-beta was much higher in this patient than in those of age-matched non-Hodgkin's lymphoma patients ( n=5) at diagnosis, decreasing after resolution of myelofibrosis.
  • Immunostaining with the TGF-beta antibody revealed that the lymphoma cells in bone marrow and spleen were positive for TGF-beta.
  • TGF-beta secreted by tumor cells was thought to stimulate the growth of fibroblasts and synthesize collagen in bone marrow and splenic fibroblasts, and play an important role in the development of marrow and splenic fibrosis in this patient.
  • This is the first report of a patient with splenic marginal zone lymphoma presenting as myelofibrosis associated with bone marrow involvement of lymphoma cells which secrete a large amount of TGF-beta.
  • [MeSH-major] Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Lymphoma / complications. Primary Myelofibrosis / etiology. Splenic Neoplasms / complications. Splenic Neoplasms / pathology. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Aged. Female. Fibrosis. Humans. Immunohistochemistry. Spleen / pathology

  • Genetic Alliance. consumer health - Myelofibrosis.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15060752.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta
  •  go-up   go-down


32. Biasoli I, Morais JC, Soares de Jesus P, Pulcheri W, Nucci M, Spector N: Application of an adapted international prognostic index for aggressive non-Hodgkin's lymphomas: good discrimination and lower survival rates in Rio de Janeiro, Brazil. Oncol Rep; 2001 Mar-Apr;8(2):441-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of an adapted international prognostic index for aggressive non-Hodgkin's lymphomas: good discrimination and lower survival rates in Rio de Janeiro, Brazil.
  • Institutions that treat patients with lymphoma must know their local therapy results and adapt their treatment strategies accordingly.
  • We also collapsed the four categories of the IPI into two categories, and applied this adapted IPI to patients with aggressive non-Hodgkin's lymphoma treated in a public university hospital.
  • Among the 72 patients treated with combination chemotherapy regimens containing doxorubicin, the following outcomes were observed for low and high risk groups, respectively: complete remission rates were 62% and 45% (p=0.2), overall survival rates were 48% and 14% (p=0.0098) and failure-free survival rates were 44% and 17% (p=0.03).
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Algorithms. Bone Marrow / pathology. Brazil. Child. Disease-Free Survival. Female. Hospitals, Public. Hospitals, University. Humans. Liver Neoplasms / mortality. Liver Neoplasms / pathology. Liver Neoplasms / therapy. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Splenic Neoplasms / mortality. Splenic Neoplasms / pathology. Splenic Neoplasms / therapy. Survival Rate. Urban Population

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11182071.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


33. Thorek DL, Tsao PY, Arora V, Zhou L, Eisenberg RA, Tsourkas A: In vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in mice. PLoS One; 2010;5(5):e10655
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: B cell depletion immunotherapy has been successfully employed to treat non-Hodgkin's lymphoma.
  • In recent years, increasing attention has been directed towards also using B-cell depletion therapy as a treatment option in autoimmune disorders.
  • METHODOLOGY/PRINCIPAL FINDINGS: Cellular imaging of the targeted population in vivo may provide significant insight towards effective therapy and a greater understanding of underlying disease mechanics.
  • Superparamagnetic iron oxide (SPIO) nanoparticles in concert with near infrared (NIR) fluorescent dyes were used to label and track primary C57BL/6 B cells.
  • Following antibody mediated B cell depletion (anti-CD79), NIR-only labeled cells were expeditiously cleared from the circulation and spleen.
  • Interestingly, B cells labeled with both SPIO and NIR were not depleted in the spleen.
  • CONCLUSIONS/SIGNIFICANCE: Whole body fluorescent tracking of B cells enabled noninvasive, longitudinal imaging of both the distribution and subsequent depletion of B lymphocytes in the spleen.
  • Quantification of depletion revealed a greater than 40% decrease in splenic fluorescent signal-to-background ratio in antibody treated versus control mice.
  • [MeSH-minor] Animals. Cells, Cultured. Fluorescence. Lymphocyte Depletion. Magnetic Resonance Imaging. Mice. Mice, Inbred C57BL. Organ Specificity. Spleen / immunology. Spleen / pathology. Staining and Labeling. Whole Body Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 May 15;95(10):3052-6 [10807768.001]
  • [Cites] Nat Biotechnol. 2000 Apr;18(4):410-4 [10748521.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] J Immunol Methods. 1994 Sep 30;175(1):79-87 [7930641.001]
  • [Cites] Int Immunol. 1997 Nov;9(11):1767-72 [9418137.001]
  • [Cites] Nat Med. 1998 Feb;4(2):245-7 [9461201.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Neurology. 1999 May 12;52(8):1701-4 [10331706.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3410-2; author reply 3412-3 [15525839.001]
  • [Cites] Arthritis Rheum. 2004 Nov;50(11):3580-90 [15529346.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):817-26 [15634903.001]
  • [Cites] Eur Radiol. 2005 Jan;15(1):4-13 [15616814.001]
  • [Cites] Arthritis Rheum. 2005 Feb;52(2):601-7 [15692974.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1096-102 [15657402.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1103-8 [15657404.001]
  • [Cites] Acad Radiol. 2005 May;12 Suppl 1:S2-6 [16106536.001]
  • [Cites] Nat Biotechnol. 2005 Nov;23(11):1407-13 [16258544.001]
  • [Cites] Mol Immunol. 2006 Feb;43(6):613-22 [15899518.001]
  • [Cites] Ann Biomed Eng. 2006 Jan;34(1):23-38 [16496086.001]
  • [Cites] Arthritis Rheum. 2006 May;54(5):1390-400 [16649186.001]
  • [Cites] Arthritis Rheum. 2006 Sep;54(9):2793-806 [16947627.001]
  • [Cites] Endocr Metab Immune Disord Drug Targets. 2006 Dec;6(4):345-50 [17214580.001]
  • [Cites] Neuroimage. 2007;37 Suppl 1:S47-58 [17611126.001]
  • [Cites] Inflamm Res. 2007 Oct;56(10):391-401 [18026695.001]
  • [Cites] Immunol Invest. 2007;36(5-6):861-85 [18161533.001]
  • [Cites] N Engl J Med. 2008 Feb 14;358(7):676-88 [18272891.001]
  • [Cites] Clin Immunol. 2008 Mar;126(3):282-90 [18226586.001]
  • [Cites] Biomaterials. 2008 Sep;29(26):3583-90 [18533252.001]
  • [Cites] J Immunol. 2008 Sep 1;181(5):2961-72 [18713966.001]
  • [Cites] J Immunol. 2008 Oct 1;181(7):4770-9 [18802080.001]
  • [Cites] Ann Rheum Dis. 2008 Dec;67(12):1724-31 [18250115.001]
  • [Cites] Blood. 2009 Apr 16;113(16):3765-72 [19029438.001]
  • [Cites] Mol Imaging Biol. 2009 May-Jun;11(3):178-87 [19034584.001]
  • [Cites] J Autoimmun. 2009 May-Jun;32(3-4):223-30 [19329279.001]
  • [Cites] AJR Am J Roentgenol. 2009 Aug;193(2):314-25 [19620426.001]
  • [Cites] J Immunol Methods. 2009 Oct 31;350(1-2):194-9 [19647745.001]
  • [Cites] Ann Neurol. 2009 Oct;66(4):460-71 [19847908.001]
  • [Cites] Curr Pharm Biotechnol. 2000 Jul;1(1):1-9 [11467356.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2029-33 [12209504.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2121-31 [12209517.001]
  • [Cites] Ann Rheum Dis. 2002 Oct;61(10):883-8 [12228157.001]
  • [Cites] Arthritis Rheum. 2002 Oct;46(10):2673-7 [12384926.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):485-9 [12640069.001]
  • [Cites] Muscle Nerve. 2003 May;27(5):611-5 [12707982.001]
  • [Cites] Science. 2003 Oct 24;302(5645):605-8 [14576425.001]
  • [Cites] N Engl J Med. 2004 Mar 4;350(10):971-80 [14999109.001]
  • [Cites] N Engl J Med. 2004 Jun 17;350(25):2572-81 [15201414.001]
  • [Cites] Arthritis Rheum. 2004 Aug;50(8):2580-9 [15334472.001]
  • [Cites] Immunol Cell Biol. 1999 Dec;77(6):499-508 [10571670.001]
  • [Cites] Cytometry. 1990;11(2):231-8 [1690625.001]
  • (PMID = 20498725.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies
  • [Other-IDs] NLM/ PMC2871797
  •  go-up   go-down


34. Safwat A: The immunobiology of low-dose total-body irradiation: more questions than answers. Radiat Res; 2000 May;153(5 Pt 1):599-604

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Low-dose total-body irradiation (TBI) is used in the treatment of chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
  • The usual practice is to give very low individual fractions (0.1 to 0.25 Gy) several times a week, to a total dose of 1.5 to 2 Gy.
  • (3) increasing the expression of Il2 receptors on the T-cell surface;.
  • (5) increasing splenic catecholamine content and lowering the serum corticosterone level; and (6) eliminating a particularly radiosensitive subset of the suppressor T cells.
  • Much is still unknown about the immunobiology of low-dose TBI, its clinical potential, and the possible synergism with chemotherapy, biological response modifiers, or immunotherapy.
  • This lack of comprehensive knowledge hampers the optimal and widespread use of this intriguing and potentially useful treatment modality in clinical practice.
  • [MeSH-minor] Animals. Humans. Lymphoma, Non-Hodgkin / radiotherapy. Mice. Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10790282.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 39
  •  go-up   go-down


35. Arcaini L, Bruno R: Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. Curr Clin Pharmacol; 2010 May;5(2):74-81
Hazardous Substances Data Bank. RIBAVIRIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas.
  • The association between hepatitis C virus (HCV) infection and B-cell non-Hodgkin's lymphomas has been demonstrated in epidemiological studies, in particular in highly endemic geographical areas such as Italy, Japan and southern parts of United States.
  • The WHO classification comprises extranodal marginal zone B-cell lymphoma of MALT type, splenic marginal zone B-cell lymphoma and nodal marginal zone B-cell lymphoma.
  • Recently, antiviral treatment has been proved to be effective in the treatment of HCV-positive patients with indolent lymphoma, prevalently of marginal zone origin.
  • Aim of this review is to illustrate the relationship between HCV infection and marginal zone lymphomas and to systematically summarize the data from the therapeutic studies where antiviral treatment with alpha-interferon with or without ribavirin was employed in patients with marginal zone lymphomas.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis C / drug therapy. Lymphoma, B-Cell, Marginal Zone / drug therapy
  • [MeSH-minor] Drug Therapy, Combination. Humans. Interferon-alpha / therapeutic use. Ribavirin / therapeutic use

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20156155.001).
  • [ISSN] 2212-3938
  • [Journal-full-title] Current clinical pharmacology
  • [ISO-abbreviation] Curr Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 49717AWG6K / Ribavirin
  • [Number-of-references] 87
  •  go-up   go-down


36. Cavalli F, Isaacson PG, Gascoyne RD, Zucca E: MALT Lymphomas. Hematology Am Soc Hematol Educ Program; 2001;:241-58

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review addresses the biology and the treatment of lymphomas arising from mucosa-associated lymphoid tissue (MALT).
  • This entity, first described in 1983, represents about 8% of all non-Hodgkin's lymphomas and was recently re-classified as "extranodal marginal zone lymphomas of MALT-type."
  • The term marginal zone lymphoma (MZL) encompasses the three closely related lymphoma subtypes of nodal, primary splenic and extranodal lymphomas of MALT type: the latter represent the vast majority of MZL.
  • MALT lymphomas arise in numerous extranodal sites, but gastric MALT lymphoma is the most common and best studied and is, therefore, the paradigm for the group as a whole. Dr.
  • Several lines of evidence suggest that gastric lymphoma arises from MALT acquired as the result of aH. pyloriinfection.
  • Very recent data suggest that both t(11;18) (q21;q21) and bcl10 nuclear expression are associated with failure to respond to this treatment. Dr.
  • Zucca reviews findings suggesting that MALT lymphoma is an antigen driven neoplasm.
  • He also presents specific guidelines for treatment of gastric lymphomas trying to shed some light on the amazingly inconsistent and confusing data in the literature.
  • Taking advantage on the more than 300 non-gastric MALT lymphomas collected by the International Extranodal Lymphoma Study Group (ILESG), Dr.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11722987.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents
  • [Number-of-references] 191
  •  go-up   go-down


37. Liebman H: Other immune thrombocytopenias. Semin Hematol; 2007 Oct;44(4 Suppl 5):S24-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immune thrombocytopenic purpura (ITP) can be classified as primary (known also as idiopathic thrombocytopenic purpura) or as secondary to an underlying condition such as a malignant or nonmalignant disorder.
  • Commonly occurring conditions associated with secondary ITP include lymphoproliferative disorders (chronic lymphocytic leukemia [CLL], Hodgkin's disease and non-Hodgkin's lymphomas), autoimmune collagen vascular diseases (systemic lupus erythematosus [SLE], thyroid disease, antiphospholipid syndrome [APS]), and chronic infections (human immunodeficiency virus [HIV], Helicobacter pylori, hepatitis C virus [HCV]).
  • The mechanism of platelet destruction in thrombocytopenias associated with lymphoproliferative disorders and collagen vascular diseases is identical to the autoimmune mechanism seen in primary ITP.
  • Drug-induced thrombocytopenias are uncommon and generally resolve quickly upon drug discontinuation, but are often attributed to other causes.
  • In patients with HCV-related cirrhotic liver disease, splenic sequestration secondary to portal hypertension and decreased production of thrombopoietin may further contribute to development of thrombocytopenia.
  • The current treatment paradigm for secondary ITP varies according to the underlying condition.
  • Standard treatments for primary ITP (corticosteroids, IVIG, anti-D, splenectomy) are often successful in secondary ITP.
  • In cases of ITP with H pylori and HCV infection, treatment should focus on the underlying disorder.
  • [MeSH-major] Blood Platelets / immunology. Thrombocytopenia / diagnosis. Thrombocytopenia / immunology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / immunology. Antiphospholipid Syndrome / complications. Antiphospholipid Syndrome / drug therapy. Antiphospholipid Syndrome / immunology. Diagnosis, Differential. Female. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter Infections / immunology. Hepatitis C / complications. Hepatitis C / drug therapy. Hepatitis C / immunology. Humans. Leukemia / complications. Leukemia / drug therapy. Leukemia / immunology. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / drug therapy. Lupus Erythematosus, Systemic / immunology. Lymphoma / complications. Lymphoma / immunology. Lymphoma / therapy. Male. Platelet Count. Thyroid Diseases / complications. Thyroid Diseases / immunology. Thyroid Diseases / therapy

  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096469.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 152
  •  go-up   go-down


38. Stasolla A, Kharrub Z, Colaiacomo MC, Cirelli G, Cirelli A, Marini M: Isolated non-Hodgkin's lymphoma of the spleen: CT findings in an AIDS patient treated with highly active antiretroviral therapy. Radiol Med; 2002 Jul-Aug;104(1-2):111-4
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated non-Hodgkin's lymphoma of the spleen: CT findings in an AIDS patient treated with highly active antiretroviral therapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / radiography. Splenic Neoplasms / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Biopsy. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Time Factors. Tomography, Spiral Computed






Advertisement